CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists

被引：0
|
作者：
Miller, MD
Lineberger, JE
Dornadula, G
Danzeisen, RC
Blau, CR
Danovich, RM
Miller, MA
Finke, PE
Oates, BD
Caldwell, CG
Chen, P
Meurer, LC
Mills, SG
Springer, MS
Petropoulos, CJ
Whitcomb, J
Huang, W
Fransen, S
Simon, AJ
Hazuda, DJ
机构：
[1] Merck Res Labs, Dept Biol Chem, West Point, PA USA
[2] Merck Res Labs, Dept Microbial Vaccine Res, West Point, PA USA
[3] Dept Med Chem, Rahway, NJ USA
[4] Dept Immunol & Rheumatol, Rahway, NJ USA
[5] ViroLog Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2003年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
61
引用
收藏
页码：U66 / U67
页数：2
相关论文
共 50 条
  • [41] Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
    Mohamed, Hager
    Gurrola, Theodore
    Berman, Rachel
    Collins, Mackenzie
    Sariyer, Ilker K.
    Nonnemacher, Michael R.
    Wigdahl, Brian
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [42] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [43] CCR5 genotype and resistance to vertical transmission of HIV-1
    Philpott, S
    Burger, H
    Charbonneau, T
    Grimson, R
    Vermund, SH
    Visosky, A
    Nachman, S
    Kovacs, A
    Tropper, P
    Frey, H
    Weiser, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193
  • [44] CCR5 promoter polymorphism and HIV-1 disease progression
    McDermott, DH
    Zimmerman, PA
    Guignard, F
    Kleeberger, CA
    Leitman, SF
    Murphy, PM
    LANCET, 1998, 352 (9131): : 866 - 870
  • [45] CCR5, vertical transmission of HIV-1, and disease progression
    Bailey, AJ
    Newell, ML
    De Rossi, A
    Giaquinto, C
    Iasci, A
    Ravizza, M
    Garcia-Rodriguez, MC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (02): : 211 - 212
  • [46] T-cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals - Implications for the therapeutic use of CCR5 antagonists
    Vincent, T
    Portales, P
    Baillat, V
    de Boever, CM
    Le Moing, V
    Vidal, M
    Ducos, J
    Clot, J
    Reynes, J
    Corbeau, P
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (03) : 305 - 309
  • [47] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [48] CCR5 genotype and the clinical course of HIV-1 infection
    Scribner, CL
    ANNALS OF INTERNAL MEDICINE, 1998, 128 (09) : 780 - 780
  • [49] Insights into interactions of the GCPR CCR5 with the HIV viral envelope
    Dogo-Isonagie, Cajetan
    Lam, Son N.
    Archaya, Priyamvada
    Kwong, Peter D.
    Bewley, Carole A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [50] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
    Benkirane, M
    Jin, DY
    Chun, RF
    Koup, RA
    Jeang, KT
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606
12345